Diabetes & CV Disease
Sort by:
Cleveland Clinic Endocrinology & Metabolism Institute
Anti-Diabetic Medications: Do They Increase The Risk of Cancer?
FEATURING
Derek LeRoith
- 168 views
- February 3, 2021
Cleveland Clinic Endocrinology & Metabolism Institute
Obesity, Diabetes and Cancer Risk: What Is the Correlation? How Do We Reduce Risks?
FEATURING
Derek LeRoith
- 1,239 views
- February 3, 2021
- 3
Cleveland Clinic Endocrinology & Metabolism Institute
Diabetes and Increased Cancer Risk: What Are the Mechanisms That Explain This Association?
FEATURING
Derek LeRoith
- 127 views
- February 3, 2021
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?
FEATURING
Barry Greenberg
- 2,016 views
- February 5, 2021
- 22
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Approaches to Treating Diabetes that Reduce CV Events: How Effective Are DPP-4 Inhibitors, GLP1-Receptor Agonists and SGLT-2 Inhibitors in Reducing MACE and Preventing HF Events?
FEATURING
Jia Shen
- 343 views
- February 5, 2021
- 4
Lucia Novak
Lispro-aabc in T1D: Which Patients Have the Most Benefit From This Ultra-Rapid-Acting Insulin?
- 427 views
- February 5, 2021
Lucia Novak
Dysglycemia in T2D: When Do We Need To Add a Mealtime Insulin? How Does Lispro aabc Prevent Dysglycemia?
- 516 views
- February 5, 2021
- 4
16th Annual Heart Failure Holiday Symposium
New Treatment Approaches to HFrEF: When to Use SGLT2, Vericiguat, Omecamtiv Mecarbil and IV Iron?
FEATURING
Mark Drazner
- 1,118 views
- February 18, 2021
- 12
Laura Nally
Ultra Rapid Acting Lispro: Review of the Literature and Prescribing Considerations
- 1,395 views
- March 1, 2021
- 3